Novo Nordisk reported better-than-expected first-quarter earnings but lowered its full-year guidance due to lower GLP-1 penetration impacted by compounding in the US. Despite the downgrade, shares rose 4.4%. The company continues to expand its GLP-1 treatments like Wegovy, with a significant increase in profits and sales, although trial results for a new obesity drug fell short of expectations. Teljes cikk (Euronews.com)